Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes
Avtorji:ID Schlingemann, Reinier O. (Avtor)
ID Noorden, Cornelis J. F. van (Avtor)
ID Diekman, Mattheus J.M. (Avtor)
ID Tiller, Anna (Avtor)
ID Meijers, Joost C.M. (Avtor)
ID Koolwijk, Pieter (Avtor)
ID Wiersinga, Wilmar M. (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://doi.org/10.2337/dc12-1951
 
.pdf PDF - Predstavitvena datoteka, prenos (716,66 KB)
MD5: 76AA20585757DED5C814FE2D75DEE8FF
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo NIB - Nacionalni inštitut za biologijo
Povzetek:OBJECTIVE Increased levels of vascular endothelial growth factor (VEGF) in human plasma samples have suggested that circulating VEGF is a cause of endothelial dysfunction in diabetes mellitus. However, artificial release of VEGF from platelets as a source of VEGF in plasma samples, as also occurs in serum samples, has not been ruled out in these studies. RESEARCH DESIGN AND METHODS We determined VEGF levels in plasma collected in both citrate and PECT, a medium that inactivates platelets, in a cross-sectional cohort of 21 healthy subjects and 64 patients with type 1 diabetes. In addition, we evaluated whether VEGF levels in both types of plasma correlated with the presence of diabetes, glycemic control, markers of in vivo or ex vivo platelet activation, and degree of diabetic retinopathy and nephropathy. RESULTS VEGF levels were invariably low in PECT plasma of both nondiabetic and diabetic subjects and were unrelated to any other diabetes-related variable studied. In contrast, VEGF levels in citrate plasma were 150% higher in diabetic patients than in control subjects and correlated with diabetes-related variables. Multiple linear regression analysis showed that levels of platelet factor 4, a marker for ex vivo platelet activation, and HbA1c were the independent predictors of VEGF levels in citrate plasma. Platelet activation, in vivo and ex vivo, was similar in diabetic persons and control subjects. CONCLUSIONS Like serum, citrate plasma is not suitable for reliable measurements of circulating VEGF. The low levels of VEGF in vivo, as represented by measurements in PECT plasma in our study, do not support a role of circulating VEGF in endothelial dysfunction in type 1 diabetes. Higher levels of VEGF in citrate plasma samples of diabetic persons do not represent the in vivo situation, but mainly originate from higher artificial ex vivo release from platelets correlating with the degree of glycemic control.
Ključne besede:vascular endothelial growth factor, VEGF, diabetes mellitus
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:15.05.2013
Leto izida:2013
Št. strani:str. 1629-1634
Številčenje:Vol. 36, no. 6
PID:20.500.12556/DiRROS-20032 Novo okno
UDK:577
ISSN pri članku:0149-5992
DOI:10.2337/dc12-1951 Novo okno
COBISS.SI-ID:4650831 Novo okno
Datum objave v DiRROS:02.08.2024
Število ogledov:307
Število prenosov:156
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Diabetes care
Skrajšan naslov:Diabetes care
Založnik:American Diabetes Association
ISSN:0149-5992
COBISS.SI-ID:25335552 Novo okno

Licence

Licenca:CC BY-NC-ND 3.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 3.0 Nedoločena
Povezava:https://creativecommons.org/licenses/by-nc-nd/3.0/deed.sl
Opis:Dovoljuje kopiranje in razširjanje vsebin v kakršnemkoli mediju in obliki. Primerno morate navesti avtorja, povezavo do licence in označiti spremembe, če so kakšne nastale. To lahko storite na kakršenkoli razumen način, vendar ne na način, ki bi namigoval na to, da dajalec licence podpira vas ali vašo uporabo dela. Te vsebine ne smete uporabiti v komercialne namene. Če vsebino predelate (remixate), uredite ali na njej gradite, spremenjene vsebine ne smete razširjati. Ne smete uporabiti pravnih določil ali tehničnih ukrepov, ki bi pravno omejili ali onemogočilo druge, da bi storili karkoli, kar licenca dovoli.

Nazaj